

## FIRST TIME GENERIC APPROVAL

<b>Brand Name</b>	Feraheme®
<b>Generic Name</b>	ferumoxytol
<b>Drug Manufacturer</b>	Sandoz Inc.

### New Drug Approval

#### TYPE OF CLINICAL UPDATE

First Time Generic

#### FDA APPROVAL DATE

Jan 15,2021

#### LAUNCH DATE

July 16,2021

#### REVIEW DESIGNATION

Standard

#### TYPE OF REVIEW

Abbreviated New Drug Application (ANDA): 206604

#### DISPENSING RESTRICTIONS

N/A

### Overview

#### INDICATION FOR USE

Ferumoxytol is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron or,
- who have chronic kidney disease (CKD).

#### MECHANISMS OF ACTION

Ferumoxytol consists of a superparamagnetic iron oxide that is coated with a carbohydrate shell, which helps to isolate the bioactive iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen and bone marrow. The iron is released from the iron-carbohydrate complex within vesicles in the macrophages. Iron then either enters the intracellular storage iron pool (e.g., ferritin) or is transferred to plasma transferrin for transport to erythroid precursor cells for incorporation into hemoglobin.

#### DOSE FORM AND STRENGTH

Injection: 510 mg iron per 17 mL (30 mg per mL) in single-dose vials

#### DOSE & ADMINISTRATION

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## FIRST TIME GENERIC APPROVAL

- The recommended dose of ferumoxytol is an initial 510 mg dose followed by a second 510 mg dose 3 to 8 days later.
- Administer ferumoxytol as an intravenous infusion in 50 to 200 mL 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP over at least 15 minutes.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.